Oligonucleotide therapeutics are becoming increasingly complex, pushing traditional manufacturing methods to their limits. As researchers develop longer sequences with sophisticated modifications, a new approach is gaining prominence: enzymatic ligation. This innovative technology is transforming how complex oligonucleotides are produced, offering solutions to longstanding manufacturing challenges.

What is enzymatic ligation?

Enzymatic ligation is a biocatalytic process that uses specialized enzymes (ligases) to join oligonucleotide fragments together. During traditional chemical synthesis, the desired molecule is built one nucleotide at a time, while in enzymatic ligation, pre-synthesized fragments are assembled into complete sequences.

The process relies on ligases, enzymes which cells mainly use to repair DNA breaks. These enzymes recognize the unligated fragment ends and catalyze the formation of phosphodiester bonds, creating seamless connections between fragments.

The enzymatic process operates under mild, physiological conditions – moderate temperatures (around 37°C), neutral pH, and aqueous solutions – unlike chemical synthesis, which involves organic solvents and reagents that can affect molecules with delicate chemical modifications.

How does enzymatic ligation work?

The process typically involves:

• Fragment synthesis: Short oligonucleotide fragments are synthesized designed with compatible ends (complementary overhangs or blunt ends).
• Fragment annealing: Hydrogen bonds are formed between the complementary oligo fragments and nicks appear in the double-stranded structure.
• Bond formation: Ligases catalyze the formation of a stable phosphodiester bond between the 3’-hydroxyl end of one nucleotide with the 5’-phosphate end of the other, effectively sealing the nicks and creating a continuous oligonucleotide chain.

The benefits of enzymatic ligation in drug development

Although understanding enzymatic ligation is important, its real impact becomes clear when compared to traditional manufacturing methods in the production of oligonucleotide APIs.

Higher overall yields

Enzymatic ligation of short oligo fragments yields higher output than full-length synthesis by minimizing coupling steps and avoiding side reactions. Ligases ensure precise alignment, producing cleaner products and simplifying purification.

Enhanced scalability

Enzymatic ligation scales seamlessly from research to commercial production. The consistency stems from the inherent nature of enzymatic catalysis as reactions proceed through well-defined molecular recognition events. Also, the modular nature of fragment assembly enables flexible production strategies, which can be particularly valuable during drug development and clinical investigations.

Cost efficiency 

Enzymatic ligation is a cost-effective method for oligonucleotide manufacturing. It reduces the need for complex purification and costly organic solvents are replaced with aqueous conditions, lowering reagent and waste disposal costs. These efficiencies make it a scalable and commercially attractive option for producing high-purity oligonucleotides.

Accommodation of complex modifications 

Enzymatic ligation enables the incorporation of complex modifications, like lipids, peptides, or PEG, under mild conditions, overcoming limitations of traditional synthesis. This flexibility allows the incorporation of multiple modifications within a single molecule, boosting their stability, targeting, and therapeutic performance.

Environmental advantages 

Operating under aqueous, near-physiological conditions, enzymatic ligation reduces the use of organic solvents and lowers chemical waste. By leveraging high-yield short fragment synthesis and subsequent assembly, it minimizes environmental impact and aligns with sustainability goals in pharmaceutical manufacturing. 

Enzymatic ligation represents a paradigm shift in oligonucleotide manufacturing. It overcomes limitations of traditional chemical synthesis by harnessing the precision and efficiency of enzymes. 

With superior yields, simpler processing, environmental benefits, and the ability to incorporate complex modifications, enzymatic ligation is becoming an essential tool in modern oligonucleotide manufacturing. 

Ready to accelerate your oligonucleotide development? Bachem’s expertise in enzymatic ligation and advanced oligonucleotide manufacturing can help bring your therapeutic concepts from discovery to commercial success. Read more in our whitepaper on Enzymatic Ligation and Other Innovative Technologies: Shaping the Future of Large-scale Oligonucleotide Manufacturing here. Contact our team today to learn how our technologies can support your next breakthrough in gene therapy.